Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: Augmentation via 5-HT(1A) receptor antagonism

Neuropharmacology

Volumn 38, Issue 8, 1999, Pages 1153-1163

  Dawson, L A ^a   Nguyen, H Q ^a   Geiger, A ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT; 5 HT(1A) receptor; Frontal cortex; Microdialysis; Noradrenaline; Venlafaxine

Indexed keywords

IDAZOXAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NORADRENALIN UPTAKE INHIBITOR; PINDOLOL; PRAZOSIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FRONTAL CORTEX; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CEREBRAL CORTEX; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; IDAZOXAN; MALE; NOREPINEPHRINE; OXADIAZOLES; PIPERAZINES; PRAZOSIN; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032970438     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00052-0     Document Type: Article

References (63)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of patients with depression treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
2. Baraban J.M., Aghajanian G.K. Suppression of firing activity of 5-HT neurones in the dorsal raphe by α-adrenoceptor antagonists. Neuropharmacology. 19:1980;355-363.
3. Beique J.-C., Debonnel G., Blier P., de Montigny C. Effects of long-term administration of venlafaxine on the function of pre and postsynaptic 5-HT and NE receptors in the rat hippocampus. Soc. Neurosci. Abstr. 24:1998;539.1.
4. Beique J.C., de Montigny C., Blier P., Debonnel G. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetien and desipramine. Br. J. Pharmacol. 125:1998;526-532.
5. Benkert O., Grunder G., Wetzel H., Hackett D. A randomized, double blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J. Psychiat. Res. 30:1996;441-451.
6. Benkert O., Grunder G., Wetzel H. Is there an advantage to venlafaxine in comparison with other antidepressants? Human Psychopharmacol. 12:1997;53-64.
7. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry. 154:1997;37-43.
8. Berzewski H., van Moffaert M., Gagiano C.A. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur. Neuropsychopharmacol. 7:1997;S37-S47.
9. Blier P., De Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:1987;24-35.
10. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
11. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 16:1997;332-338.
12. 1A receptors in augmenting antidepressant activity in the mouse forced swimming test. Psychopharmacology. 136:1998;226-234.
13. Clerc G.E., Ruimy P., Verdeay-Pailles J. A double blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol. 9:1995;138-143.
14. 1A autoreceptor in vivo. Br. J. Pharmacol. 124:1998;206-212.
15. Dawson L.A., Routledge C. Differential effects of potassium channel blockers on extracellular levels of serotonin and dopamine in the striatum of conscious rats. Br. J. Pharmacol. 116:1996;3260-3264.
16. 1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur. J. Pharmacol. 345:1998;41-46.
17. 1A receptor blockade, on extracellular concentrations of 5-HT: a microdialysis study. Soc. Neurosci. Abstr. 24:1998;438.11.
18. 1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (±) pindolol. Eur. J. Pharmacol., (submitted).
19. 2-adrenoceptors. Br. J. Pharmacol. 78:1983;489-505.
20. Delgado J.M.R., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Physchiatry. 47:1990;411-418.
21. 1A receptors. Neurochem. Res. 21:1996;557-562.
22. Engleman E.A., Robertson D.W., Thompson D.C., Perry K.W., Wong D.T. Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J. Neurochem. 66:1996;599-602.
23. Feigner J.P. The role of venlafaxine in rational antidepressant therapy. J. Clin. Psychiatry. 55(Suppl. A):1994;62-68.
24. 1A receptor antagonist, WAY100635. Eur. J. Pharmacol. 281:1995;81-86.
25. 1A receptor antagonist and a SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115:1995;1064-1070.
26. 1A autoreceptors and noradrenergic mechanisms. Psychopharmacology. 130:1997;261-268.
27. Gobert A., Rivet J.-M., Cistarelli L., Millan M.J. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J. Neurochem. 68:1997;1326-1329.
28. 1B receptors with WAY100635 and GR127935. J. Neurochem. 68:1997;1159-1163.
29. Guelfi J.D., White C., Hackett D., Guichoux J.Y., Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiat. 56:1995;450-458.
30. Haddjeri N., de Montigny C., Bleir P. Modulation of the firing activity of noradrenergic reutones in the rat locous coeruleus by the 5-hydroxtryptamine system. Br. J. Pharmacol. 120:1997;865-875.
31. Hjorth S., Carlsson A. Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis. Neuropharmacology. 24:1985;1143-1146.
32. Hjorth S., Carlsson A. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur. J. Pharmacol. 129:1986;131-138.
33. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J. Neurochem. 60:1993;776-779.
34. 1A autorecptors and a1-adrenoceptors in the inhibition of 5-HT release-BMY7378 and prazosin. Neuropharmacology. 34:1995;615-620.
35. Hjorth S. Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur. J. Pharmacol. 303:1996;183-186.
36. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav. Brain Res. 73:1996;281-283.
37. 1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology. 36:1997;461-465.
38. Hyttel J. Pharmacological characterization of the selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9:1994;19-26.
39. 1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Bioch. Behav. 54:1996;143-147.
40. Kihara T., Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibito, on extracellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. 272:1995;177-183.
41. Michell P.J., Fletcher A. Venlafaxine exhibits preclinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology. 32:1993;1001-1009.
42. 1A receptor antagonist, WAY100635. Behav. Pharmacol. 8:1997;585-606.
43. Montgomery S.A. Rapid onset of action of venlafaxine. Int. Clin. Psychopharmacol. 10(Suppl. 2):1995;21-27.
44. de Montigny C., Debonnel G., Bergeron R., St Andre E., Blier P. Venlafaxine in treatment resistant depression: open-label multicentre study. Am. Coll. Neuropharmacol. 34:1995;158.
45. Moyer J.A., Muth E.A., Haskins J.T., Sigg E.B. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45030 and Wy-45881. Soc. Neurosci. Abstr. 10:1984;76.12.
46. Mucci M. Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol. 11:1997;S33-S37.
47. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielson S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:1986;4493-4497.
48. Muth E.A., Moyer J.A., Haskins J.T., Andree T.H., Husbands G.E.M. Biochemical, neurophysiological, and behavioural effects of Wy-45233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23:1991;191-199.
49. Nelson J.C., Mazure C.M., Bowers M.B., Jatlow P.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry. 48:1991;303-307.
50. Nemeroff C.B. Augmentation strategies in patients with refractory depression. Depress. Anxiety. 4:1997;169-181.
51. Nierenberg A., Feigner J.P., Rudolph R., Cole J.O., Sullivan J. Venlafaxine for treatment resisitant unipolar depression. J. Clin. Psychopharmacol. 4:1994;419-423.
52. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
53. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
54. Potter W.Z. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin. Psychiatry. 57:1996;4-8.
55. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 15:1996;349-360.
56. Rudolph R., Entsuah R., Derivan A. Early clinical response in depression to venlafaxine hydrochloride. Biol. Psychiat. 29:1991;630S.
57. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Letts. 171:1994;183-186.
58. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol. 96:1989;283-290.
59. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol. 121:1997;941-946.
60. 1D receptor antagonist. Behav. Brain Res. 73:1996;157-161.
61. Tao R., Hjorth S. α2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn-Schmiedebergs Arch. Pharmacol. 345:1992;137-143.
62. Tian Y., Eaton M.J., Goudreau J.L., Lookingland K.J., Moore K.E. Neurochemical evidence that 5-hydroxytryptaminergic neurons tonically inhibit noradrenergic neurons terminating in the hypothalamus. Brain Res. 607:1993;215-221.
63. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12:1997;81-89.